Early Warning for Breast Cancer Metastasis: Molecular Clues from
Limitations of Traditional Tests and New Possibilities
Breast cancer is the most common cancer among women worldwide, accounting for over one-third of new female cancer cases. Despite advances in treatment, around 20% of early-stage patients still experience metastasis. Traditional markers like CA15-3 and CEA lack sensitivity and fail to reflect real-time changes, highlighting the clinical need for more responsive and trackable diagnostic tools.
Research Advances
EG BioMed has collaborated with Taipei Medical University Hospital and the Breast Center of Shuang Ho Hospital for over eight years on long-term follow-up research. EG BioMed developed a methylation-based assay targeting the genes GCM2 and TMEM240 to monitor breast cancer progression and treatment response. In validation, the assay achieved an AUC of 0.930, with 89.4% sensitivity, 95.6% specificity, and an overall accuracy of 91.5%. Compared to conventional biomarkers such as CA15-3 and CEA, this method demonstrated superior detection performance and clinical responsiveness, with consistent results across diverse populations.
This study demonstrates that methylation changes in GCM2 and TMEM240 reliably reflect breast cancer progression and treatment response, enabling faster and more accurate clinical decisions. As a non-invasive blood test, it can be used before, during, and after treatment to complement existing tumor markers and support real-time monitoring and personalized care. EG BioMed is committed to advancing this technology to benefit breast cancer patients worldwide.
Dr. Chin-Sheng Hung, Chief Medical Officer of EG BioMed, Director of the Department of Surgery at Taipei Medical University Hospital, and a renowned breast surgeon, presented this study at the AACR 2025 annual meeting.
Want to stay updated on EG BioMed’s latest technologies and research progress?
Follow us on LinkedIn、Facebook, and Instagram for real-time updates and insights!